New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Moderna, Inc.

MRNA

Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.

Revenue
+29.2%
EPS
n/m
Free cash flow
n/m
Total debt
+13,550.0%

Quarter to September 2026, against a year earlier

195.12 4.21 −2.11%

After hours trading: 199.30, up 2.14%, last trade Fri 7:57pm Eastern.

Market cap
$79.6B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
3/9
ROIC
−35.1%
Net debt / EBITDA
1.8×
Payout ratio
—

Moderna, Inc. (MRNA) revenue by segment, product and region

Where the money comes from and where it goes

Fiscal 2025: revenue by products and services, and margins
COVID 1,810 93.11%
Stand-ready manufacturing revenue 80 4.12%
Grant revenue 22 1.13%
Collaboration Arrangement, Including Arrangements With Affiliate 13 0.67%
Licensing and royalty revenue 11 0.57%
RSV 8 0.41%
Gross margin 55.35%
Operating margin (158.13%)
Pre-tax margin (142.39%)

Revenue by product or service $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2018 FY2016
Collaboration Arrangement — — — — — 123 69
Collaborative Arrangement With Affiliate — — — — — — 32
Also reported: a second breakdown of the same revenue
COVID 1,810 3,084 6,671 18,435 — — —
Stand-ready manufacturing revenue 80 0 0 — — — —
Grant revenue 22 37 94 388 735 13 7
Collaboration Arrangement, Including Arrangements With Affiliate 13 48 83 440 61 — —
Licensing and royalty revenue 11 42 0 0 — — —
RSV 8 25 0 0 — — —
Other revenue 126 127 — — 796 — —
Net product sales 1,818 3,109 — — — — —
Revenue 1,944 3,236 6,848 19,263 18,471 135 108

Gross profit by product or service $m, and margin

Revenue by region $m

Line FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
United States 1,199 1,785 1,895 5,150 6,177 764 55 89
Rest of world 692 853 3,598 7,298 5,448 6 0 —
Europe 53 598 1,355 6,815 6,846 33 5 —
Non-US — — — — — — — 46
Revenue 1,944 3,236 6,848 19,263 18,471 803 60 135

As each company reports them in its 10-K and 10-Q filings, in US dollars. Where a later filing recast a year's segments, the year is shown as recast; a period whose breakdown does not add up to the company's revenue is left out.